Taysha Gene Therapies Inc To Discuss TSHA-120 GAN Program Update Call Transcript
Hello, and welcome to Taysha Gene Therapies GAN Program Update Webcast. (Operator Instructions) As a reminder, this webcast is being recorded today, January 31, 2022.
I will now turn the call over to Dr. Kimberly Lee, Senior Vice President of Corporate Communications and Investor Relations. Dr. Lee, Please go ahead.
Thank you. Good morning, and welcome to Taysha's GAN program update conference call and webcast. Earlier this morning, Taysha issued a press release reporting clinical efficacy and safety data for the high-dose cohort and long-term durability data for TSHA-120 and giant axonal neuropathy or GAN. A copy of this press release is available on the company's website and through our SEC filings.
On this call, we will review the reported data and discuss next steps for our clinical development program. Joining me on today's call are RA Session, II, Taysha's President, CEO and Founder; Dr. Suyash Prasad, Chief Medical Officer and Head of Research and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |